University Medical Center

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study

Retrieved on: 
Monday, April 8, 2024
Observational study, Cardiovascular disease, University Medical Center, Patient, Angina, Șaeș, CCS, American College, University Medical Center Utrecht, DRS, Royal Brompton Hospital, MACE, Pharmaceutical industry

These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.

Key Points: 
  • These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.
  • Results were presented earlier today at the 73rd Annual Scientific Sessions of the American College of Cardiology in Atlanta, GA.
    REDUCER-I is a post-market, multi-center, observational study designed to collect long-term outcomes on Shockwave Reducer in a large, ‘real-world’ population of 400 patients.
  • “Results from the REDUCER-I study continue to demonstrate the safety and effectiveness of Shockwave Coronary Sinus Reducer as a novel therapy for refractory angina,” said Dr. Verheye.
  • Results from COSIRA-II are intended to support the regulatory filing for US FDA approval of Shockwave Reducer.

BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs

Retrieved on: 
Wednesday, April 3, 2024
MagForce, Computer science, University Medical Center, Gesellschaft mit beschränkter Haftung, University, Doctor of Philosophy, Medtech, Quality management, Quality, Heart, CSO, ISO, Nursing

Leipzig, Germany, April 3, 2024 – BellaSeno GmbH , an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced today that Dr. Thomas Lingner was appointed Chief Technology Officer and Inga Freyert was promoted to VP Quality and Regulatory Affairs.

Key Points: 
  • Leipzig, Germany, April 3, 2024 – BellaSeno GmbH , an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced today that Dr. Thomas Lingner was appointed Chief Technology Officer and Inga Freyert was promoted to VP Quality and Regulatory Affairs.
  • Inga Freyert served as BellaSeno´s Head of Quality Management since 2022 and was promoted to VP Quality Management and Regulatory Affairs in early 2024.
  • Before joining bess pro GmbH, Inga Freyert worked as Quality & Regulatory Specialist / Junior Q&R Manager at MagForce AG, Berlin.
  • “We warmly welcome Dr. Thomas Lingner and Inga Freyert to their new roles at BellaSeno,” said Dr. Mohit Chhaya, CEO of BellaSeno.

Making Long-Term Memories Requires Nerve-Cell Damage

Retrieved on: 
Wednesday, March 27, 2024
Inflammation, Radulović, Psychiatry, Brain, TLR9, COVID, Gene, DNA repair, DSM-IV codes, Cell division, Genome instability, University Medical Center, Infection, Memory, Organelle, Hippocampus, Mouse, DNA, Albert Einstein, Nature, Cancer, Toll-like receptor 9, Neuron, Northwestern University, Doctor of Philosophy, Alzheimer's disease, Genome, Aarhus University, Cytoplasm, Cell, Dominic, B.A, Encephalitis, Ageing, Vaccine

"But our findings suggest that inflammation in certain neurons in the brain's hippocampal region is essential for making long-lasting memories."

Key Points: 
  • "But our findings suggest that inflammation in certain neurons in the brain's hippocampal region is essential for making long-lasting memories."
  • But looking more closely, we found, to our surprise, that TLR9 was activated only in clusters of hippocampal cells that showed DNA damage."
  • But in this population of hippocampal neurons, the DNA damage appeared to be more substantial and sustained.
  • Importantly, the researchers found that blocking the TLR9 inflammatory pathway in hippocampal neurons not only prevented mice from forming long-term memories but also caused profound genomic instability, i.e, a high frequency of DNA damage in these neurons.

Crearene AG and Alzchem Group AG: Successful addition of creatine to dialysis patient treatments

Retrieved on: 
Wednesday, March 13, 2024
Patient safety, Dialysis, Creatine, Trial of the century, University Medical Center Groningen, Research, University Medical Center, Patient, Pharmaceutical industry

Crearene AG and Alzchem Group AG: Successful addition of creatine to dialysis patient treatments

Key Points: 
  • Crearene AG and Alzchem Group AG: Successful addition of creatine to dialysis patient treatments
    As part of their cooperation, Alzchem Group AG and Crearene AG announced in October 2023 that a clinical study on the use of creatine in dialysis treatments had been launched.
  • The aim is to demonstrate the technical feasibility, patient safety and dose finding of creatine-based dialysis treatment solutions.
  • Using specially purified creatine from the Alzchem Group, a University Medical Center Groningen team, led by Prof. Dr. Stephan J.L.
  • Based on the promising initial results, Alzchem Group AG and Crearene AG have extended their collaboration to develop creatine-based treatment solutions for medical applications until the end of 2025.

Clinical Research on Photon-Counting CT Begins with Radboud University Medical Center

Retrieved on: 
Tuesday, February 27, 2024
Photon, Perfusion, European Congress of Radiology, Canon Medical Systems Corporation, University Medical Center, European, X-ray, ECR, Agent handling, Radboud University Medical Center, Radboud University Nijmegen, Health, Teaching, Congress, Research, Medical imaging

Otawara, Japan, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Canon Medical Systems Corporation (hereinafter "Canon Medical"; President and CEO: Toshio Takiguchi; headquarters: Otawara, Tochigi, Japan) has completed the second installation of its Canon photon-counting CT (PCCT) system worldwide at Radboud University Medical Center (Chair: Dr. Bertine Lahuis; location: Nijmegen, the Netherlands), and clinical research began in late January.

Key Points: 
  • Otawara, Japan, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Canon Medical Systems Corporation (hereinafter "Canon Medical"; President and CEO: Toshio Takiguchi; headquarters: Otawara, Tochigi, Japan) has completed the second installation of its Canon photon-counting CT (PCCT) system worldwide at Radboud University Medical Center (Chair: Dr. Bertine Lahuis; location: Nijmegen, the Netherlands), and clinical research began in late January.
  • PCCT is expected to be the next generation of X-ray CT
    Radboud University Medical Center is an academic medical center specializing in patient care, scientific research, teaching, and training.
  • The Department of Radiology at Radboud University Medical Center leads one of the best research groups in Europe, working with more than 150 researchers on advanced studies to provide patient care and improve health care.
  • Canon Medical entered into an agreement on joint clinical research with Radboud University Medical Center on November 14, 2023,*1 and clinical research aimed at early practical application of PCCT was started, led by Prof. Mathias Prokop, Chairman of the Department of Radiology at Radboud University Medical Center.

Dr. Frank J. Veith Joins the Board of Directors of ViTAA Medical Solutions

Retrieved on: 
Thursday, February 29, 2024
Software, Research, General Health, Technology, Public Relations, Investor Relations, Clinical Trials, Science, Surgery, Biotechnology, Communications, Other Science, Health, Chin Na, Cleveland Clinic, University Medical Center, Harvard Medical School, Medical corps, Vascular disease, Vitaa, Brigham and Women's Hospital, Lung transplantation, Medicine, Management

ViTAA Medical Solutions, Inc., a leading innovator of precision vascular health designed to improve patient outcomes across the globe, is thrilled to announce the appointment of Frank J. Veith, M.D., a distinguished figure in the field of vascular surgery, to its Board of Directors.

Key Points: 
  • ViTAA Medical Solutions, Inc., a leading innovator of precision vascular health designed to improve patient outcomes across the globe, is thrilled to announce the appointment of Frank J. Veith, M.D., a distinguished figure in the field of vascular surgery, to its Board of Directors.
  • "We are honored to welcome Dr. Veith to our Board of Directors," said Mitchel Benovoy, CEO of ViTAA Medical Solutions.
  • Dr. Veith's addition to the Board underscores ViTAA's commitment to excellence and innovation in the development of medical technologies.
  • "I am honored and excited to join the ViTAA Board of Directors and contribute to their mission of transforming vascular care," said Dr. Veith.

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

Retrieved on: 
Wednesday, February 14, 2024
PD, Newcastle University, Analyst, Research, University Medical Center, Internet, PI, Synucleinopathy, Biomarker, Therapy, Genetics, Task force, Columbia University, KOL, Symptomatic treatment, Pharmaceutical industry

“Beyond Symptomatic Treatment of Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”

Key Points: 
  • “Beyond Symptomatic Treatment of Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”
    GBA-associated Parkinson’s Disease & other Synucleinopathies: current unmet medical needs and needed therapies.
  • Discussion of recent in vivo data for GT-02287 as a best-in-class small molecule, for the treatment of GBA-Parkinson’s Disease and other neurodegenerative diseases.
  • His research interests are focused on the understanding of the molecular mechanisms of neurodegenerative diseases such as Parkinson’s, Huntington’s, and Alzheimer’s disease.
  • He is Chair of the Task Force on the Biological Definition of Parkinson’s Disease of Internation Parkinson and Movement Disorder Society.

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Retrieved on: 
Tuesday, February 13, 2024
Therapy, Master of Science, Max Planck Society, Marketing, Psoriasis, Inhalation, I&I, University Medical Center, Inflammation, Drug development, Growth, Al-Quds, GMP, Business development, CDMO, COVID-19, VHH, Novartis, Nutrition, Hebrew University of Jerusalem, Head, Research, Pharmaceutical industry

JERUSALEM, Feb. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as Head of Business Development and Sales.

Key Points: 
  • JERUSALEM, Feb. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as Head of Business Development and Sales.
  • Scinai's broad pharmaceutical development experience, along with its end-to-end biologics drug development and GMP manufacturing facility, drove the Q3 2023 launch of Scinai Bioservices, a boutique end-to-end CDMO business unit, to assist biotech companies efficiently bring their products to market.
  • In addition to expanding the CDMO's business development and sales activities, Halpert will support partnering and out-licensing activities with mid and large cap pharma companies with which Scinai plans on bringing the NanoAbs through clinical trials and towards commercialization.
  • Halpert commented, "I am thrilled to join Scinai where I'll be leading business development and sales of our state-of-the-art end-to-end CDMO services in the global biotech arena.

New Study Redefines Reconstructive Surgery

Retrieved on: 
Tuesday, February 13, 2024
Hospital, University Medical Center, Professor, Manuscript, Risk, AG, Disease, Health, Patient, Dentistry

BILLERBECK, Germany, Feb. 13, 2024 /PRNewswire/ -- In a study led by Prof. Dragu, Professor and Head of the Plastic Surgery Department at the University Medical Center in Dresden, Germany, the effectiveness of MatriDerm®, a dermal template manufactured by MedSkin Solutions Dr Suwelack, AG, has been demonstrated. The new publication, which marks a significant advancement in reconstructive surgery, highlights MatriDerm®'s role in reducing operating room (OR) time, avoiding flap surgery in up to 80% of cases, and eliminating donor site morbidities associated with traditional flap procedures.

Key Points: 
  • The new publication, which marks a significant advancement in reconstructive surgery, highlights MatriDerm®'s role in reducing operating room (OR) time, avoiding flap surgery in up to 80% of cases, and eliminating donor site morbidities associated with traditional flap procedures.
  • This study is truly significant in not only impacting clinical practice but also underlines the economic benefits of MatriDerm®."
  • MatriDerm®'s ability to avoid complex flap surgery in most cases of this published specific morbid patient group represents a major shift in current treatment paradigms.
  • This offers the patients a less invasive but comparable and successful reconstructive result."

New Study Redefines Reconstructive Surgery

Retrieved on: 
Tuesday, February 13, 2024
Hospital, University Medical Center, Professor, Manuscript, Risk, AG, Disease, Health, Patient, Dentistry

BILLERBECK, Germany, Feb. 13, 2024 /PRNewswire/ -- In a study led by Prof. Dragu, Professor and Head of the Plastic Surgery Department at the University Medical Center in Dresden, Germany, the effectiveness of MatriDerm®, a dermal template manufactured by MedSkin Solutions Dr Suwelack, AG, has been demonstrated. The new publication, which marks a significant advancement in reconstructive surgery, highlights MatriDerm®'s role in reducing operating room (OR) time, avoiding flap surgery in up to 80% of cases, and eliminating donor site morbidities associated with traditional flap procedures.

Key Points: 
  • The new publication, which marks a significant advancement in reconstructive surgery, highlights MatriDerm®'s role in reducing operating room (OR) time, avoiding flap surgery in up to 80% of cases, and eliminating donor site morbidities associated with traditional flap procedures.
  • This study is truly significant in not only impacting clinical practice but also underlines the economic benefits of MatriDerm®."
  • MatriDerm®'s ability to avoid complex flap surgery in most cases of this published specific morbid patient group represents a major shift in current treatment paradigms.
  • This offers the patients a less invasive but comparable and successful reconstructive result."